368 related articles for article (PubMed ID: 15355924)
1. Soluble type II transforming growth factor-beta receptor inhibits established murine malignant mesothelioma tumor growth by augmenting host antitumor immunity.
Suzuki E; Kapoor V; Cheung HK; Ling LE; DeLong PA; Kaiser LR; Albelda SM
Clin Cancer Res; 2004 Sep; 10(17):5907-18. PubMed ID: 15355924
[TBL] [Abstract][Full Text] [Related]
2. A novel small-molecule inhibitor of transforming growth factor beta type I receptor kinase (SM16) inhibits murine mesothelioma tumor growth in vivo and prevents tumor recurrence after surgical resection.
Suzuki E; Kim S; Cheung HK; Corbley MJ; Zhang X; Sun L; Shan F; Singh J; Lee WC; Albelda SM; Ling LE
Cancer Res; 2007 Mar; 67(5):2351-9. PubMed ID: 17332368
[TBL] [Abstract][Full Text] [Related]
3. Eradication of intraperitoneal and distant tumor by adenovirus-mediated interferon-beta gene therapy is attributable to induction of systemic immunity.
Odaka M; Sterman DH; Wiewrodt R; Zhang Y; Kiefer M; Amin KM; Gao GP; Wilson JM; Barsoum J; Kaiser LR; Albelda SM
Cancer Res; 2001 Aug; 61(16):6201-12. PubMed ID: 11507073
[TBL] [Abstract][Full Text] [Related]
4. Adoptive transfer of tumor-reactive transforming growth factor-beta-insensitive CD8+ T cells: eradication of autologous mouse prostate cancer.
Zhang Q; Yang X; Pins M; Javonovic B; Kuzel T; Kim SJ; Parijs LV; Greenberg NM; Liu V; Guo Y; Lee C
Cancer Res; 2005 Mar; 65(5):1761-9. PubMed ID: 15753372
[TBL] [Abstract][Full Text] [Related]
5. SD-208, a novel transforming growth factor beta receptor I kinase inhibitor, inhibits growth and invasiveness and enhances immunogenicity of murine and human glioma cells in vitro and in vivo.
Uhl M; Aulwurm S; Wischhusen J; Weiler M; Ma JY; Almirez R; Mangadu R; Liu YW; Platten M; Herrlinger U; Murphy A; Wong DH; Wick W; Higgins LS; Weller M
Cancer Res; 2004 Nov; 64(21):7954-61. PubMed ID: 15520202
[TBL] [Abstract][Full Text] [Related]
6. Immune-mediated eradication of tumors through the blockade of transforming growth factor-beta signaling in T cells.
Gorelik L; Flavell RA
Nat Med; 2001 Oct; 7(10):1118-22. PubMed ID: 11590434
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy for human renal cell carcinoma by adoptive transfer of autologous transforming growth factor beta-insensitive CD8+ T cells.
Wang L; Wen W; Yuan J; Helfand B; Li Y; Shi C; Tian F; Zheng J; Wang F; Chen L; Liang L; Zhou L; Lee C; Chen Z; Guo Y; Wang H; Zhang Q; Qin W
Clin Cancer Res; 2010 Jan; 16(1):164-73. PubMed ID: 20028741
[TBL] [Abstract][Full Text] [Related]
8. Adenovirus vector-mediated overexpression of a truncated form of the p65 nuclear factor kappa B cDNA in dendritic cells enhances their function resulting in immune-mediated suppression of preexisting murine tumors.
Lee JM; Mahtabifard A; Yamada R; Crystal RG; Korst RJ
Clin Cancer Res; 2002 Nov; 8(11):3561-9. PubMed ID: 12429647
[TBL] [Abstract][Full Text] [Related]
9. Tumorigenicity of mouse thymoma is suppressed by soluble type II transforming growth factor beta receptor therapy.
Won J; Kim H; Park EJ; Hong Y; Kim SJ; Yun Y
Cancer Res; 1999 Mar; 59(6):1273-7. PubMed ID: 10096559
[TBL] [Abstract][Full Text] [Related]
10. Induction and maintenance of T-cell response to a nonimmunogenic murine mesothelioma cell line requires expression of B7-1 and the capacity to upregulate class II major histocompatibility complex expression.
Leong C; Marley J; Loh S; Robinson B; Garlepp M
Cancer Gene Ther; 1996; 3(5):321-30. PubMed ID: 8894251
[TBL] [Abstract][Full Text] [Related]
11. T-cell receptor transgenic analysis of tumor-specific CD8 and CD4 responses in the eradication of solid tumors.
Marzo AL; Lake RA; Robinson BW; Scott B
Cancer Res; 1999 Mar; 59(5):1071-9. PubMed ID: 10070965
[TBL] [Abstract][Full Text] [Related]
12. Synergistic antitumor effects of regulatory T cell blockade combined with pemetrexed in murine malignant mesothelioma.
Anraku M; Tagawa T; Wu L; Yun Z; Keshavjee S; Zhang L; Johnston MR; de Perrot M
J Immunol; 2010 Jul; 185(2):956-66. PubMed ID: 20548032
[TBL] [Abstract][Full Text] [Related]
13. CD28 costimulation overcomes transforming growth factor-beta-mediated repression of proliferation of redirected human CD4+ and CD8+ T cells in an antitumor cell attack.
Koehler H; Kofler D; Hombach A; Abken H
Cancer Res; 2007 Mar; 67(5):2265-73. PubMed ID: 17332357
[TBL] [Abstract][Full Text] [Related]
14. Cationic lipid:bacterial DNA complexes elicit adaptive cellular immunity in murine intraperitoneal tumor models.
Lanuti M; Rudginsky S; Force SD; Lambright ES; Siders WM; Chang MY; Amin KM; Kaiser LR; Scheule RK; Albelda SM
Cancer Res; 2000 Jun; 60(11):2955-63. PubMed ID: 10850443
[TBL] [Abstract][Full Text] [Related]
15. Infiltration of tumor-reactive transforming growth factor-beta insensitive CD8+ T cells into the tumor parenchyma is associated with apoptosis and rejection of tumor cells.
Zhang Q; Jang TL; Yang X; Park I; Meyer RE; Kundu S; Pins M; Javonovic B; Kuzel T; Kim SJ; Van Parijs L; Smith N; Wong L; Greenberg NM; Guo Y; Lee C
Prostate; 2006 Feb; 66(3):235-47. PubMed ID: 16173028
[TBL] [Abstract][Full Text] [Related]
16. Suppression of tumor metastasis by blockade of transforming growth factor beta signaling in bone marrow cells through a retroviral-mediated gene therapy in mice.
Shah AH; Tabayoyong WB; Kundu SD; Kim SJ; Van Parijs L; Liu VC; Kwon E; Greenberg NM; Lee C
Cancer Res; 2002 Dec; 62(24):7135-8. PubMed ID: 12499244
[TBL] [Abstract][Full Text] [Related]
17. Transforming growth factor-beta released by PPD-presenting malignant mesothelioma cells inhibits interferon-gamma synthesis by an anti-PPD CD4+ T-cell clone.
Valle MT; Porta C; Megiovanni AM; Libener R; Mele L; Gaudino G; Strizzi L; Guida R; Toma S; Mutti L
Int J Mol Med; 2003 Feb; 11(2):161-7. PubMed ID: 12525871
[TBL] [Abstract][Full Text] [Related]
18. Mechanisms of tolerance induced by transforming growth factor-beta-treated antigen-presenting cells: CD8 regulatory T cells inhibit the effector phase of the immune response in primed mice through a mechanism involving Fas ligand.
Kosiewicz MM; Alard P; Liang S; Clark SL
Int Immunol; 2004 May; 16(5):697-706. PubMed ID: 15096489
[TBL] [Abstract][Full Text] [Related]
19. Activation of tumor-associated macrophages by the vascular disrupting agent 5,6-dimethylxanthenone-4-acetic acid induces an effective CD8+ T-cell-mediated antitumor immune response in murine models of lung cancer and mesothelioma.
Jassar AS; Suzuki E; Kapoor V; Sun J; Silverberg MB; Cheung L; Burdick MD; Strieter RM; Ching LM; Kaiser LR; Albelda SM
Cancer Res; 2005 Dec; 65(24):11752-61. PubMed ID: 16357188
[TBL] [Abstract][Full Text] [Related]
20. Peptide epitopes from the Wilms' tumor 1 oncoprotein stimulate CD4+ and CD8+ T cells that recognize and kill human malignant mesothelioma tumor cells.
May RJ; Dao T; Pinilla-Ibarz J; Korontsvit T; Zakhaleva V; Zhang RH; Maslak P; Scheinberg DA
Clin Cancer Res; 2007 Aug; 13(15 Pt 1):4547-55. PubMed ID: 17671141
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
